SK Bioscience Signs 39.5 Billion KRW Supply Contract with Novavax
[Asia Economy Reporter Lee Jung-yoon] SK Bioscience announced on the 19th that it has signed a contract with Novavax to produce prefilled syringe (PFS) formulations of the COVID-19 vaccine worth 39.5 billion KRW.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
This amount corresponds to 4.25% of last year's sales, and the contract period is from the day before until December 31 of this year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
